Researchers all over the world are invited to attend DiPIA 2024

Dates: 9 - 12 September, 2024
Venue: Kistamässan Exhibition & Congress Centre, Arne Beurlings Torg 5, 164 40 Kista, Sweden

What is DiPIA?

DiPIA, or Developments in Protein Interaction Analysis, is a global scientific conference hosted by Cytiva. We bring peers together from across the industry to share best practices, research, and new applications. This conference is dedicated to the surface plasmon resonance (SPR) technology as featured in our Biacore™ SPR systems.

The theme for this year’s DiPIA is Exploring the Unknown. Expect to see the past, present, and future of exploration. Stay tuned for more updates on the theme as the event nears.


Ticket Prices

Standard entry tickets: €850
Price includes local VAT of 25%. Payments will be handled by our partners at Pro-SPR within 5 business days of form fill.

Tickets are strictly limited so act fast to secure your place. Fill in the form on this page to register for attendance. Our partners at Pro-SPR will be in touch to confirm your spot and handle payments. The registration fee includes attendance to the event, lunches provided, the welcome reception and the gala dinner.

This event is organized by Cytiva. The registration fee includes attendance to the event, lunches provided, the welcome reception and the gala dinner. Accommodation may be allocated by Cytiva but is not included in the event fee. Registrant information will be passed on to our partners at Pro-SPR and Cvent to help organize this event and provide a smoother experience for you. Information will not be used for any purpose outside of DiPIA 2024.

Screenshot 2024-04-17 at 15.46.15.png

Learn more


Registration for DiPIA 2024 is now closed.


If you are interested in attending or have any questions, please reach out to your local Cytiva Biacore representative.

Insert text

Someone famous in Source Title

Panel 3 header

Insert text

Learn more


Speakers and topics

The gallery of speakers invited to host talks and speak to you on all things SPR, along with the subject area they will be coming to speak about. This list will be updated with each new wave of speaker announcements.

  • Phil Addis, Sygnature Discovery - Pushing the limits: Establishing scalable SPR assays for molecular glue discovery
  • Jason Baardsnes, National Research Council Canada - SARS Cov2 – Ace2 binding assays for kinetics, selection and QC
  • Aurelie Castan, Novartis Pharma AG - Characterization of antibody binding to FcɣRIIIa by SPR and affinity chromatography MS
  • Göran Dahl, AstraZeneca
  • Gregory Descrescenzo, Montreal Poltyech
  • Tim van den Hooven, Genmab - FcRn characterization: an odyssey to (and through) qualification
  • Ute Jucknischke, Roche Diagnostics - Kinetics with native biomarkers – The reality check for antibodies
  • David Kallenberg, UCB - Fragment screening on the Biacore 8K+ and an evaluation of the Biacore Intelligent Analysis™ machine learning software
  • Matthias Kania, Boeringer Ingelheim Pharma GmbH & Co. K - Applications of Biacore technology in a regulated biopharmaceutical environment
  • Matthias Knape, Boeringer Ingelheim Pharma GmbH & Co. K - Applications of Biacore technology in a regulated biopharmaceutical environment
  • Patrik Nygren, BioArctic
  • Dr. Hanno Sjuts, Sanofi
  • Pedro M.F. Sousa, iBet - Extract2chip - Bypassing protein purification in drug discovery using SPR
  • Rob Staehlin, Purdue University - Lipid-protein interactions in virus assembly, budding and virus spread
  • David Zollman, University of Dundee - Expanding the biophysical toolbox for targeted protein degradation drug discovery

Learn more


Panel 4 with video

Insert text

Insert text

Learn more


Agenda

Agenda and schedules are subject to change. All times listed are in CEST.

Monday, 9 September, 2024

On the first day, we will welcome you all to Sweden at the site for a reception lunch. Have a bite to eat and chat with us and other attendees.
Once fed and settled, we will commence the first workshops of the week. Simultaneously, a second group will be taken to the Cytiva Uppsala site to see where the magic happens.

Time Speaker Company Title
Registration and welcome lunch
11:00–17:00           Registration open
11:00–12:45 Reception lunch
Parallel session 1
12:45–15:00 Nestor Santiago and Gillian Goodwin Cytiva Biacore™ system assay development revisited - Recipe for successful SPR data
Cynthia Shuman and Eric Roush Cytiva Slow and steady wins the race: Techniques for measuring slow dissociation rates using Biacore SPR system
Christin Radon and Emeric Gueneau Cytiva Thinking outside 1:1 – Discover how to approach assay design for induced proximity and targeted protein degradation
15:00–15:30 Break
15:30–17:00 Anja Drescher and Mike Murphy Cytiva Facilitating comparability with SPR-based surrogate potency assays and sensorgram comparison
John Sinfield and Shannon Bryan Cytiva Biacore™ Insight Software – A look beneath the surface: interesting facts and hidden features that will improve your workflows from start to finish
Parallel session 2
12:45–17:45 Uppsala site tour
Welcome drinks
18:30 Welcome drinks

Tuesday, 10 September, 2024

We hear from the first of our guest speakers, presenting talks from their research and learnings.
Breaks will take place throughout the day to allow you to browse our exhibition and speak to colleagues and Cytiva specialists. Poster viewing will be available at the end of the day.

Time Speaker Company Title
Low molecular weight drug discovery
8:30–10:30  Göran Dahl AstraZeneca Navigating the dynamic role of SPR in modern drug discovery
John Quinn Genentech Affinity-clamping of an ion-channel receptor composed of six transmembrane helices enabled Biacore™-based assays that progressed early chemical matter
David Kallenberg UCB Fragment screening on the Biacore 8K+ and an evaluation of the Biacore Intelligent Analysis™ machine learning software
Tonia Aristotelous Broad Institute SPR adventures: turning tiny hits into big wins
10:30–11:00 Coffee break and exhibition
Biotherapeutics drug discovery
11:00–13:00       Ute Jucknischke Roche Diagnostics Kinetics with native biomarkers – the reality check for antibodies
Masaru Muraoka Chugai Pharmaceutical Assessing the binding properties of the next-generation T Cell Engager, SAIL66
Aurelie Castan Novartis Pharma AG Characterization of antibody binding to FcɣRIIIa by SPR and affinity chromatography MS
Thomas Moon BMS Out of office: maximizing unattended run time from high throughput antibody screening using the Biacore 8K+
13:00–14:00 Lunch
Advanced SPR applications in research
14:00–16:00 David Zollman University of Dundee Expanding the biophysical toolbox for targeted protein degradation drug discovery
Gregory Decrescenzo Montreal Polytech Integration of SPR measurements for at-line characterization of Mab glycosylation
Pedro M.F. Sousa Merck - iBET Extract2chip - Bypassing protein purification in drug discovery using SPR
Kazuhiro Ohara Chugai Pharmaceutical Molecular interaction analysis for drug discovery of orally bioavailable cyclic peptide
16:00–17:00 Poster and exhibition

Wednesday, 11 September, 2024

We hear from the first of our guest speakers, presenting talks from their research and learnings.
Breaks will take place throughout the day to allow you to browse our exhibition and speak to colleagues and Cytiva specialists. Poster viewing will be available at the end of the day.

Time Speaker Company Title
QC and analytical development
8:30–10:30 Matthias Knape & Matthias Kania Boehringer Ingelheim Pharma GmbH & Co. K Applications of Biacore technology in a regulated biopharmaceutical environment
Jana Taylor GSK Biacore™ 8K+: Delivering high throughput methods for characterising multivalent proteins
Tim van den Hooven Genmab FcRn characterization: an odyssey to (and through) qualification
Jason Baardsnes National Research Council Canada The use of SPR at the National Research Council Canada during the COVID pandemic response
10:30–11:00    Coffee break and exhibition
Low molecular weight drug discovery
11:00–12:30          Peter Brown BicycleTx How SPR supports the development of bicycles – a novel class of therapeutics
Phil Addis Sygnature Discovery Pushing the limits: Establishing scalable SPR assays for molecular glue discovery
Anna Uvarova Novartis Making the right measurement: Biophysical tools to dissect ternary complex formation mechanisms
12:30–13:30 Lunch
Biotherapeutics drug discovery
13:30–15:00 Hanno Sjuts Sanofi Better biologics by design: structure-function relationships to support antibody developability
Patrik Nygren BioArctic Biacore as a tool for studying antibody interaction with human derived Aβ-fibrils
Nik Lane BMS to be announced
15:00–15:30 Poster, exhibition, and coffee    
Advanced SPR applications in research
15:30–17:00 Rob Staehlin Purdue University Lipid-protein interactions in virus assembly, budding and virus spread
Lauren Hartley Griffith University Exploring glycan interactions, and going into the vast array of glycan interactions, including proteins, glycoproteins, whole cells, viruses, lectins and also glycans
Gregor Hagelüken University of Bonn Binding of cyclic nucleotides activates antiviral signalling by a CRISPR-associated Lon protease
18:30–21:00 Gala dinner

Thursday, 12 September, 2024

Time Speaker Company Title
QC and analytical development
 8:30–10:40 Klaus Hochleitner Cytiva Characterization and selection of antibodies for lateral flow diagnostics using SPR technology
Daisy May Thomas SERB Pharmaceuticals Development of an SPR method for measurement of antivenom potency  
Danielle Wagner National Institute of Health Serum antibody epitope mapping for development of next generation COVID-19 vaccines  
10:40–11:10 Coffee break and exhibition
Poster winner and closing of DiPIA 2024
11:10–12:30 Poster winner presentation
Paul Belcher Cytiva Looking back to move forward - the path to enlightenment for experimental reproducibility
Closing remarks
12:30 Light lunch
Finish

Card image

Excellent performance

Achieve high titers of infectious virus, which you can boost further by using enhancers.

Enhanced product quality

Minimize DNase-resistant host cell DNA inside capsids.

Innovative

Access advances in cell line engineering across the entire portfolio to support transition between cell lines.

Collaborative

Benefit from a comprehensive suite of regulatory support services.

Card image

Excellent performance

Achieve high titers of infectious virus, which you can boost further by using enhancers.

Enhanced product quality

Minimize DNase-resistant host cell DNA inside capsids.

Innovative

Access advances in cell line engineering across the entire portfolio to support transition between cell lines.

Collaborative

Benefit from a comprehensive suite of regulatory support services.

ELEVECTA packaging cell line. Contains all genes except the transgene. Allows streamlining the screening of assets that use the same capsid to target the same tissue type.

Streamlined screening

Efficiently screen multiple assets that target the same tissue type.

Cost-effective approach

Reduce your plasmid costs with single-plasmid transfection compared with triple transfection.

One cell line to clinic

Go to clinic with one cell line and simplify your regulatory asks when you’re targeting the same tissue type across your programs.


CAR T and TCR manufacturing


We are looking forward to seeing you at ISCT. Join us for an exciting new product reveal over a glass of champagne on “date and time” If you are working in cell therapy, check out all the sessions showcasing what’s next in autologous CAR T and TCR manufacturing.

Product showcase

An introduction of the new, end-to-end solution from Cytiva to manufacture autologous CAR T therapies at commercial scale.
Presenters: Stephanie Bourin, Senior Product Manager at Cytiva and Bertrand Foucaut, Senior Product Manager at Cytiva

Corporate session

Thursday 30 May, 6-7 PM
Deliver what's next: fueling the future of autologous CAR T therapy
Emmanuel Abate, President Genomic Medicine at Cytiva; George White, Cell Therapy Product Management Leader at Cytiva; Beate Mueller-Tiemann, Chief Technology Officer at Cytiva; Sadik Kassim, Chief Technology Officer at Danaher; Angela Johnson, Global Regulatory and Compliance Leader, Cytiva; KITE and OMNIA BIO

Poster

End-to-end manufacturing of autologous CAR T cell therapies with a new cell therapy manufacturing platform.
More details to come.
Presenters: Federico Franchi, R& Manager MBO Biology and Marine De Lageneste, Biology lead Senior Scientist

New product demos

An introduction of the new, end-to-end solution from Cytiva to manufacture autologous CAR T therapies at commercial scale.
Presenters: Stephanie Bourin, Senior Product Manager at Cytiva and Bertrand Foucaut, Senior Product Manager at Cytiva

Can't make it to ISCT? Join us on 13 June to discover what’s next in autologous CAR T manufacturing: LINK TO VIRTUAL LAUNCH REGISTRATION PAGE

Beyond CAR T


Interested in what's next?

Launch and patient access concurrent session

Friday 31 May 2024, 3:45-4:45 PM
Industrializing manufacturing and distribution
Martin Westberg, Vice President, Cell Therapy, Cytiva

Posters

Regulatory T cell expansion in the Xuri™ cell expansion system W25
Presenter: Mojtaba Parvizi, Global Fast Trak Leader — Cell Therapy

Closed, semi-automated harvest of iPSC scale-up workflow using the Sepax™ C-Pro with CultureWash protocol
Presenter: Mojtaba Parvizi, Global Fast Trak Leader — Cell Therapy

RNA-LNP


Are you working on RNA-LNPs? Discover the potential of our solutions from concept to clinic.

Product showcase

Friday 31 May, 12:30-12:45 PM
Precision NanoSystems, now part of Cytiva
Samuel Clarke, Director R&, Precision NanoSystems – now part of Cytiva.

Posters

Optimization of multiplex CRISPR-Cas9 editing of human primary T cells using lipid nanoparticles (LNPs) and subsequent off-target evaluation
Meenakshi Swaminathan, Associate Scientist, Product Development, Cytiva

Strategies for producing clinical and commercial RNA-LNP drug products
Robert Young, Senior Engineer, Systems, Cytiva

Oral abstract presentation

Efficient gene editing in CD34+ hematopoietic stem and progenitor cells using non-viral lipid nanoparticles
Stella Park, Associate Scientist, Product Development, Cytiva

Aseptic Filling


Are you interested in Aseptic Filling?

Global showcase presentation

Thursday 30 May, 1:15-1:30 PM, Theatre A Slot: 10A
New containment solutions for automated aseptic filling for gene therapy

Presenters: Jim Thompson, Director of R&, West Pharmaceutical Services and Brent Lieffers, Senior Director of Innovation Advocacy, Cytiva

Form title

Form sub title